

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:	:		
JINYANG HONG, ET AL.	:		
APPLICATION NO.:	NOT YET ASSIGNED	:	Examiner: Carlos A. Azpuru (anticipated)
FILING DATE:	HEREWITH	:	Group Art Unit: 1615 (anticipated)
TITLE: NMDA RECEPTOR AGONIST	:		
PHARMACEUTICAL COMPOSITION	:		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

PRELIMINARY AMENDMENT

Prior to examination of the application, Applicants amend as follows:

In the Specification

On Page 1, immediately below the Title of the Invention (as lines 2-3), please insert the following paragraph:

-- The present application is a continuation of U.S. application Serial No. 10/010,827, filed December 5, 2001, an allowed application, which claims priority of U.S. provisional application 60/255,372 filed December 13, 2000. The complete text and claims of the 10/010,827 application are incorporated by reference herein, as if fully set forth. --

In the Claims

Prior to calculating the Filing Fee herein, please cancel claims 5-9 without prejudice.

Respectfully submitted,

Date: August 19, 2003



E. Victor Donahue
Attorney for Applicant(s)
Reg. No. 35,492

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-2739